Top 3 Picks
2026 Outlook
Key trends in the Orthopedic Devices sector include the rise of robotic-assisted surgeries and personalized implants, which are expected to enhance patient outcomes and reduce recovery times, projecting sector revenue to reach $60-70 billion by 2026 as per Statista. Regulatory approvals for new devices and a shift toward value-based healthcare are likely to favor companies with strong R&D pipelines, though supply chain disruptions and reimbursement challenges could pose risks. Overall, the sector's outlook remains positive, with innovations in biomaterials and digital health integration poised to drive double-digit growth in subsegments like knee and hip replacements.
Complete Rankings
| Rank | Stock | Score | Price | Market Cap |
|---|---|---|---|---|
|
1
|
Inogen Inc
|
67.8 | $6.63 | $228M |
|
2
|
Mine Safety Incorporated
|
63.4 | $162.24 | $6.8B |
|
3
|
Alpha Pro Tech, Ltd.
|
60.3 | $4.55 | $50M |
|
4
|
Intuitive Surgical Inc.
|
59.4 | $561.98 | $157.0B |
|
5
|
Zimmer Biomet Holdings, Inc.
|
58.9 | $90.02 | $19.6B |
|
6
|
Nutriband Inc. Common Stock
|
58.6 | $4.43 | $87M |
|
7
|
HeartSciences Inc. Common Stock
|
58.1 | $3.14 | $9M |
|
8
|
Cadre Holdings, Inc.
|
57.6 | $41.12 | $1.5B |
|
9
|
STERIS plc
|
57.4 | $250.04 | $23.8B |
|
10
|
Enovis Corporation
|
56.3 | $26.51 | $1.7B |
|
11
|
Edwards Lifesciences Corp
|
55.3 | $85.33 | $44.8B |
|
12
|
Myomo Inc.
|
54.4 | $0.99 | $35M |
|
13
|
Sanara MedTech Inc. Common Stock
|
54.2 | $23.10 | $274M |
|
14
|
Align Technology Inc
|
54.1 | $156.03 | $9.2B |
|
15
|
Lakeland Industries Inc
|
54.1 | $8.85 | $142M |
In-Depth Analysis: Top Orthopedic Devices Stocks
INGN
Inogen Inc is a medical technology company that develops and manufactures portable oxygen concentrators used to deliver oxygen therapy to patients with chronic respiratory conditions. Its key product, the Inogen One system, is a lightweight alternative to traditional, stationary oxygen concentrator systems and oxygen tanks. The firm sells its products to home medical equipment providers and also rents products directly …
Inogen Inc stands out in the medical devices sector, particularly for its innovative portable oxygen concentrators that enhance patient mobility and quality of life for those with chronic respiratory conditions, potentially influencing broader device innovations in areas like orthopedics through advanced portability features. Its Inogen One system represents a shift toward lightweight, user-friendly alternatives to traditional devices, addressing growing demands for at-home and on-the-go medical solutions.
Inogen's negative profit margin of -7.3% and ROE of -13.3% indicate ongoing challenges in achieving profitability and efficient use of equity, reflecting potential issues with cost management and operational efficiency. However, the company's 4.0% revenue growth suggests positive top-line expansion, which could improve financial health if margins are optimized through scaling operations.
Inogen's 4.0% revenue growth and Tradestie Score of 67.8 signal moderate potential for upside, driven by increasing demand for portable medical devices amid an aging population projected to grow by 2026. The company's focus on innovative products like the Inogen One system positions it to capture market share in the expanding home healthcare sector, potentially leading to profitability improvements as operational efficiencies are realized. By 2026, advancements in technology and market penetration could result in stock appreciation, making it a speculative buy for investors seeking growth in medical devices.
MSA
MSA Safety Inc makes safety products that are used to protect workers in the oil and gas and mining industries. The products include breathing apparatuses, fall protection, portable gas detection systems, industrial head protection, fire and rescue helmets, and fixed gas and flame detection systems. End markets include the fire service, contractor, industrial, mining, oil and gas, and utilities industries. …
Although MSA Safety Inc. operates primarily in industrial safety rather than the Orthopedic Devices sector, its products play a crucial role in preventing workplace injuries in high-risk industries like oil and gas, which could indirectly reduce the demand for orthopedic devices by minimizing accidents such as falls or gas exposures.
MSA Safety Inc. exhibits robust profitability with a 15.0% profit margin, indicating efficient cost management and strong operational performance, while its 23.4% ROE demonstrates effective use of shareholder equity to generate returns. The company's 8.3% revenue growth reflects steady expansion in demand for its safety products, supported by a P/E ratio of 22.9 that suggests the stock is reasonably priced relative to its earnings potential.
Investors should consider buying MSA Safety Inc. stock in 2026 due to its consistent 8.3% revenue growth, driven by increasing safety regulations in oil, gas, and mining sectors, which positions the company for continued expansion. The high 23.4% ROE indicates strong potential for reinvesting profits into innovation and market share growth, potentially enhancing stock value. Additionally, with a Tradestie Score of 63.4, the stock offers a moderate risk profile in a resilient industry essential for worker protection amid global industrial demands.
APT
Alpha Pro Tech Ltd is in the business of protecting people, products and environments. It is developing, manufacturing and marketing a line of disposable protective apparel and infection control products for the cleanroom, industrial, pharmaceutical, medical and dental markets. It also manufacture a line of building supply construction weatherization products that are sold under the Alpha Pro Tech brand name. …
Alpha Pro Tech Ltd. matters in the Orthopedic Devices sector by supplying essential disposable protective apparel and infection control products that ensure sterile environments during surgical procedures, including orthopedics, thereby reducing contamination risks and supporting patient safety. Its focus on medical and pharmaceutical markets positions it as a key player in maintaining high standards of hygiene amid growing regulatory demands in healthcare.
Alpha Pro Tech's profit margin of 6.2% indicates moderate profitability in a competitive sector, while its ROE of 5.9% suggests efficient but improvable use of equity. With revenue growth at 3.7% and a P/E ratio of 12.8, the company demonstrates financial stability and reasonable valuation, supported by a Tradestie Score of 60.3, reflecting average market appeal.
Alpha Pro Tech's steady revenue growth of 3.7% signals potential for expansion in the healthcare sector, particularly with increasing demand for infection control products in orthopedic applications by 2026. Its P/E ratio of 12.8 implies the stock is undervalued, offering an attractive entry point for investors seeking moderate profitability gains from a 6.2% margin. As global healthcare needs evolve, the company's protective solutions could drive higher returns, making it a compelling buy for long-term portfolio growth.
ISRG
Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed more than 9,500 da Vinci systems in hospitals worldwide, with more than 5,500 installations in the US and a growing number in emerging markets.
Intuitive Surgical matters in the Orthopedic Devices sector as a leader in robotic-assisted surgery, with its da Vinci systems enabling precise minimally invasive procedures that improve outcomes in orthopedic applications. Having placed over 9,500 systems worldwide, the company drives innovation and market adoption, setting standards for efficiency and patient recovery in this specialized field.
Intuitive Surgical exhibits strong profitability with a 28.6% profit margin and 16.9% ROE, demonstrating efficient cost management and effective equity utilization. Its 22.9% revenue growth further highlights robust financial health, supported by expanding demand for its robotic systems despite a high P/E ratio of 75.7 indicating premium valuation.
Intuitive Surgical's 22.9% revenue growth signals strong potential for continued expansion in the robotic surgery market by 2026, driven by increasing adoption of minimally invasive orthopedic procedures. The company's high P/E ratio of 75.7 reflects investor confidence in future earnings, bolstered by its dominant market position with over 9,500 systems installed. Additionally, with a Tradestie Score of 59.4, the stock presents a compelling opportunity amid technological advancements and growing healthcare demands.
ZBH
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two-thirds of total revenue is derived from sales of large joints; another fourth …
Zimmer Biomet matters in the Orthopedic Devices sector due to its leading market share in the US reconstructive implants market, achieved through strategic acquisitions like Centerpulse in 2003 and Biomet in 2015, which have solidified its position as a dominant player in designing and supplying essential orthopedic surgical equipment.
Zimmer Biomet's profitability shows a 10.1% profit margin and 6.4% ROE, indicating moderate efficiency in generating profits from sales and equity, though there is potential for optimization. The company's 9.7% revenue growth highlights strong financial health, driven by increasing demand in the orthopedic sector despite the relatively low ROE.
Investors should consider buying ZBH stock by 2026 given its 9.7% revenue growth, which signals robust demand for orthopedic devices amid an aging population. The company's market leadership, bolstered by key acquisitions, positions it for innovation and potential market share expansion in reconstructive implants. Additionally, with a P/E ratio of 22.5, the stock offers a reasonable valuation for long-term growth in the expanding orthopedic sector.
NTRB
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.
Nutriband Inc. matters in the Orthopedic Devices sector as its AVERSA technology addresses opioid abuse prevention, which is crucial for managing post-surgical pain in orthopedic procedures, potentially improving patient outcomes and safety. This innovation positions the company as a key player in integrating pharmaceutical solutions with orthopedic care to mitigate risks associated with pain management drugs.
Nutriband's ROE of -136.1% indicates severe financial strain, reflecting losses that erode shareholder equity, while a revenue growth decline of -46.4% highlights operational challenges and shrinking market presence. These metrics collectively suggest the company is in a precarious financial health state, likely due to high R&D costs in early-stage development.
By 2026, Nutriband's AVERSA technology could capitalize on the growing demand for abuse-deterrent opioids, driven by the ongoing opioid crisis and potential FDA approvals, potentially boosting revenue from transdermal products. The Tradestie Score of 58.6/100 indicates moderate upside potential, and if the company successfully partners with pharmaceutical firms, it could achieve market penetration in orthopedic pain management. This positions NTRB as an attractive buy for investors seeking exposure to innovative healthcare solutions amid sector recovery.
HSCS
HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare …
HeartSciences Inc. matters in the Orthopedic Devices sector as its AI-powered ECG technology enhances early detection of heart disease, potentially integrating with orthopedic care to improve overall patient outcomes and reduce comorbidities in musculoskeletal patients. By advancing cardiac screening tools, the company contributes to broader medical device innovation that supports holistic healthcare approaches in sectors like orthopedics.
The company's ROE of -220.4% indicates severe financial strain and lack of profitability, highlighting challenges in generating returns on equity amid high operational costs. However, with a remarkable revenue growth of 653.8%, HeartSciences demonstrates strong market traction and potential for scaling operations, which could lead to improved financial health if losses are managed effectively.
HeartSciences' explosive 653.8% revenue growth underscores its potential for rapid expansion in AI-driven medical diagnostics, positioning the company to capture a larger share of the medical technology market by 2026. The Tradestie Score of 58.1 suggests moderate upside, supported by ongoing innovations in ECG technology that could enhance early heart disease detection and drive adoption in healthcare systems. By 2026, as AI integration in devices becomes mainstream, investors may benefit from increased demand for HeartSciences' solutions, potentially leading to significant stock appreciation if the company achieves profitability.
CDRE
Cadre Holdings Inc is engaged in the design and manufacture of a diversified product portfolio of critical safety and survivability equipment to protect first responders, federal agencies, outdoor recreation, and personal protection markets. The Company's equipment provides critical protection to allow its users to safely and securely perform their duties and protect those around them in hazardous or life-threatening situations. …
Cadre Holdings, Inc. matters in the Orthopedic Devices sector through its expertise in designing protective equipment that could intersect with orthopedic safety solutions, such as gear for first responders that mitigates injury risks in high-impact scenarios. This positions the company as a key player in enhancing survivability and protection, potentially extending to orthopedic applications in personal and professional settings.
Cadre Holdings exhibits moderate profitability with a 7.3% profit margin, indicating efficient cost management relative to revenue, while its 14.2% ROE demonstrates strong returns on shareholder equity. The company's 42.5% revenue growth reflects robust financial health and market expansion, though the 37.6 P/E ratio suggests investors are paying a premium for anticipated future earnings.
Cadre Holdings' 42.5% revenue growth signals strong potential for continued market penetration in safety equipment by 2026, driven by increasing demand from first responders and federal agencies. With a solid 14.2% ROE, the company is effectively utilizing equity to generate profits, supporting long-term value creation. Additionally, the 37.6 P/E ratio indicates market optimism for growth, making CDRE an appealing buy for investors seeking exposure to expanding protective gear markets.
STE
Steris is an Ireland-domiciled medical technology company focused on sterilization services and infection prevention. The company is the global leader in contract sterilization services, ensuring the safe delivery of single-use and implantable medical equipment to hospitals around the world. Steris also sells sterilizers, washer-disinfectors, and other decontamination equipment and supplies for use by care provider facilities and in biopharma manufacturing …
Steris matters in the Orthopedic Devices sector as the global leader in contract sterilization services, which are essential for ensuring the safety of implantable devices like joint replacements and prosthetics, thereby supporting the sector's growth and compliance with stringent health regulations. Its infection prevention expertise directly enables hospitals to deliver high-quality orthopedic care worldwide, making it a critical player in the supply chain.
Steris exhibits solid profitability with a 12.1% profit margin and 10.1% ROE, indicating efficient operations and effective use of shareholder equity in generating returns. The 9.9% revenue growth highlights financial health and expansion potential, though the high P/E ratio of 36.7 suggests the stock is priced at a premium relative to current earnings.
Steris's 9.9% revenue growth and leadership in sterilization services position it to capitalize on increasing demand for orthopedic devices driven by an aging population and rising surgical volumes by 2026. The company's strong profitability metrics, including a 12.1% profit margin, indicate resilience and potential for earnings upside amid healthcare innovations. Furthermore, as global infection prevention standards evolve, Steris's market dominance could lead to enhanced market share and superior returns for investors in 2026.
ENOV
Enovis Corp is a medical technology company that offers medical devices and services across the continuum of patient care, from injury prevention to joint replacement to rehabilitation after surgery, injury, or degenerative disease. Its reportable segments are Prevention & Recovery (P&R) and Reconstructive (Recon). The company generates the maximum revenue from the Prevention & Recovery segment, which includes products that …
Enovis Corporation matters in the Orthopedic Devices sector due to its comprehensive portfolio spanning prevention, reconstruction, and recovery, addressing critical needs from injury prevention to post-surgical rehabilitation. Its Prevention & Recovery and Reconstructive segments position it to benefit from the growing demand for orthopedic solutions amid an aging population and rising chronic conditions.
Enovis's negative profit margin of -61.2% and ROE of -51.0% highlight significant challenges in achieving profitability and efficient equity utilization, potentially stemming from high R&D and operational costs in the competitive medical device industry. However, the company's 8.6% revenue growth indicates underlying business expansion that could improve financial health with better cost management and market penetration.
Enovis's 8.6% revenue growth demonstrates strong potential in the expanding orthopedic devices market, driven by increasing demand for joint replacements and rehabilitation solutions, making it an attractive buy by 2026. The company's focus on innovative segments like Prevention & Recovery could capture greater market share as healthcare trends shift toward proactive care. With a Tradestie Score of 56.3, indicating moderate upside, investors may see value in this stock's turnaround potential amid sector growth projections.
Methodology
Stocks are ranked using the Tradestie Score, a proprietary 0-100 rating that combines fundamental quality (profitability, balance sheet strength), growth metrics (revenue and earnings growth), valuation (P/E, PEG ratio), and momentum factors. Scores are updated daily based on the latest market data. Learn more about our methodology.